APA (7th ed.) Citation

Regnault, A., Bunod, L., Loubert, A., Brose, M. S., Hess, L. M., Maeda, P., . . . Payakachat, N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: Psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. SpringerOpen.

Chicago Style (17th ed.) Citation

Regnault, Antoine, et al. Assessing Tolerability with the Functional Assessment of Cancer Therapy Item GP5: Psychometric Evidence from LIBRETTO-531, a Phase 3 Trial of Selpercatinib in Medullary Thyroid Cancer. SpringerOpen.

MLA (9th ed.) Citation

Regnault, Antoine, et al. Assessing Tolerability with the Functional Assessment of Cancer Therapy Item GP5: Psychometric Evidence from LIBRETTO-531, a Phase 3 Trial of Selpercatinib in Medullary Thyroid Cancer. SpringerOpen.